Sale of Equity Interests in Theravance Respiratory Company, LLC and Discontinued Operations - Summary of discontinued operations (Details) - USD ($) $ in Thousands		12 Months Ended
	Jul. 20, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Feb. 21, 2020
Schedule of Equity Method Investments [Line Items]
Provision for income tax expense		$ (178,974)
Total net income from discontinued operations		$ 964,956	$ 65,645	$ 16,806
9.5% Non-Recourse 2035 Notes
Schedule of Equity Method Investments [Line Items]
Interest rate (as a percent)		9.50%	9.50%		9.50%
9.0% Non-Recourse 2033 Notes
Schedule of Equity Method Investments [Line Items]
Interest rate (as a percent)		9.00%	9.00%
Disposed of by Sale | TRC | Royalty Pharma
Schedule of Equity Method Investments [Line Items]
Income from investments in TRC, LLC		$ 53,237	$ 103,987	68,438
Transaction-related legal expenses (prior to July 20, 2022)		(5,057)
Loss on extinguishment of debt		(24,022)		(15,464)
Net gain from sale of equity interests in TRC, LLC	$ 1,141,100	1,141,084
Provision for income tax expense		(178,974)
Total net income from discontinued operations		964,956	65,645	16,806
Disposed of by Sale | TRC | Royalty Pharma | 9.5% Non-Recourse 2035 Notes
Schedule of Equity Method Investments [Line Items]
Interest expenses		$ (21,312)	$ (38,342)	(32,193)
Disposed of by Sale | TRC | Royalty Pharma | 9.0% Non-Recourse 2033 Notes
Schedule of Equity Method Investments [Line Items]
Interest expenses				$ (3,975)